-
2022-503112-17-00
5
2024-10-16
Limb-girdle muscular dystrophy, type 2E/R4 (LGMD2E/R4) or β-sarcoglyca
-
2022-502825-17-00
4
2024-10-07
Melanoma
-
2023-504231-41-01
4
2024-10-02
Locally advanced or metastatic urothelial cancer
-
2023-504445-31-00
4
2024-09-19
Carcinoma, Head and Neck
-
2023-504918-29-00
5
2024-08-22
Hormone receptor positive breast cancer
-
2023-507555-29-00
9
2024-08-16
LA/mGC/GEJC (locally advanced unresectable or metastatic gastric cance
-
2023-509566-38-00
9
2024-08-05
gastroesophageal junction adenocarcinoma
-
2023-503699-25-00
5
2024-07-15
Progressive Pulmonary Fibrosis
-
2023-503697-21-01
5
2024-06-24
Idiopathic pulmonary fibrosis
-
2023-506267-33-00
3
2024-05-29
Non-Hodgkin Lymphoid Malignancies
-
2023-507402-13-00
5
2024-04-03
Multiple myeloma
-
2022-501606-35-01
11
2024-02-21
Platinum-sensitive epithelial ovarian, fallopian tube, or primary
peri
-
2023-503521-19-00
5
2024-02-09
Duchenne muscular dystrophy (DMD)
-
2022-501157-36-00
6
2024-02-07
Critically ill patients who are dependent on high level medical care i
-
2024-511337-35-00
4
2023-11-16
The trial will include patients with so called "fusion-driven", metast
-
2022-503058-37-00
5
2023-11-10
Advanced Gastrointestinal Stromal Tumor
-
2023-504506-11-00
7
2023-10-09
Advanced Solid Tumors
-
2023-503290-38-00
4
2023-09-05
Bronchiectasis
-
2023-505140-19-00
5
2023-07-31
Childhood Idiopathic Nephrotic Syndrome
-
2022-500544-38-00
5
2023-06-05
Advanced Breast Cancer
-
2023-509810-13-00
4
2023-05-13
Acute Lymphoblastic Leukemia (ALL)
-
2024-510635-21-00
5
2023-05-09
warm autoimmune haemolytic anaemia (wAIHA)
-
2022-501152-28-00
4
2022-12-21
Breast Cancer
-
2024-516066-11-00
5
2022-08-31
Patients with newly diagnosed, histologically confirmed, primary advan